• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疏水滑动:1型人类免疫缺陷病毒蛋白酶耐药性的一种可能机制。

Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease.

作者信息

Foulkes-Murzycki Jennifer E, Scott Walter Robert Peter, Schiffer Celia A

机构信息

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA.

出版信息

Structure. 2007 Feb;15(2):225-33. doi: 10.1016/j.str.2007.01.006.

DOI:10.1016/j.str.2007.01.006
PMID:17292840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2044563/
Abstract

Hydrophobic residues outside the active site of HIV-1 protease frequently mutate in patients undergoing protease inhibitor therapy; however, the mechanism by which these mutations confer drug resistance is not understood. From analysis of molecular dynamics simulations, 19 core hydrophobic residues appear to facilitate the conformational changes that occur in HIV-1 protease. The hydrophobic core residues slide by each other, exchanging one hydrophobic van der Waal contact for another, with little energy penalty, while maintaining many structurally important hydrogen bonds. Such hydrophobic sliding may represent a general mechanism by which proteins undergo conformational changes. Mutation of these residues in HIV-1 protease would alter the packing of the hydrophobic core, affecting the conformational flexibility of the protease. Therefore these residues impact the dynamic balance between processing substrates and binding inhibitors, and thus contribute to drug resistance.

摘要

在接受蛋白酶抑制剂治疗的患者中,HIV-1蛋白酶活性位点之外的疏水残基经常发生突变;然而,这些突变产生耐药性的机制尚不清楚。通过对分子动力学模拟的分析,19个核心疏水残基似乎促进了HIV-1蛋白酶中发生的构象变化。疏水核心残基相互滑动,以一个疏水范德华接触交换另一个,几乎没有能量损失,同时维持许多结构上重要的氢键。这种疏水滑动可能代表了蛋白质发生构象变化的一种普遍机制。HIV-1蛋白酶中这些残基的突变会改变疏水核心的堆积,影响蛋白酶的构象灵活性。因此,这些残基影响处理底物和结合抑制剂之间的动态平衡,从而导致耐药性。

相似文献

1
Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease.疏水滑动:1型人类免疫缺陷病毒蛋白酶耐药性的一种可能机制。
Structure. 2007 Feb;15(2):225-33. doi: 10.1016/j.str.2007.01.006.
2
Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.HIV-1蛋白酶耐药变体Gly48Thr/Leu89Met中疏水性滑动机制缺陷和活性位点扩展:沙奎那韦结合效力丧失的机制
Biochemistry. 2015 Jan 20;54(2):422-33. doi: 10.1021/bi501088e. Epub 2015 Jan 7.
3
Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.通过分子动力学模拟理解 HIV-1 蛋白酶奈非那韦耐药突变 D30N 在亚型 B 和 C 中的作用。
J Mol Graph Model. 2010 Sep;29(2):137-47. doi: 10.1016/j.jmgm.2010.05.007. Epub 2010 Jun 11.
4
Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.系统分子动力学、MM-PBSA 和从头计算方法研究 11 种双重和多种突变导致的 HIV-1 PR 中沙奎那韦耐药机制。
J Phys Chem B. 2014 Aug 14;118(32):9538-52. doi: 10.1021/jp502687q. Epub 2014 Jul 31.
5
A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.一项关于 HIV-1 蛋白酶与达芦那韦、安普那韦、茚地那韦和沙奎那韦复合物因 flap 突变 I50V 导致耐药机制的贡献:系统 MM-PBSA 和热力学积分研究。
J Chem Inf Model. 2013 Aug 26;53(8):2141-53. doi: 10.1021/ci4002102. Epub 2013 Jul 24.
6
Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.关于HIV-1蛋白酶非活性位点突变V77I导致奈非那韦耐药性分子机制的结构研究
BMC Bioinformatics. 2015;16 Suppl 19(Suppl 19):S10. doi: 10.1186/1471-2105-16-S19-S10. Epub 2015 Dec 16.
7
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.耐药性突变对HIV-1蛋白酶动力学特性的影响以及安普那韦和达芦那韦的抑制作用。
Sci Rep. 2015 May 27;5:10517. doi: 10.1038/srep10517.
8
Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.探讨 CRF01_AE HIV-1 蛋白酶活性位点、非活性位点突变及其协同作用的耐药机制:分子动力学模拟和自由能计算。
J Biomol Struct Dyn. 2019 Jul;37(10):2608-2626. doi: 10.1080/07391102.2018.1492459. Epub 2019 Jan 10.
9
Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.1型人类免疫缺陷病毒蛋白酶对奈非那韦的耐药机制。
J Phys Chem B. 2005 Jan 13;109(1):565-74. doi: 10.1021/jp046860+.
10
How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.突变如何在抵抗药物结合的同时保持HIV-1蛋白酶的功能。
Biochemistry. 2017 Jun 13;56(23):2907-2920. doi: 10.1021/acs.biochem.7b00139. Epub 2017 Jun 1.

引用本文的文献

1
Subtype-Specific HIV-1 Protease and the Role of Hinge and Flap Dynamics in Drug Resistance: A Subtype C Narrative.特定亚型的HIV-1蛋白酶以及铰链区和瓣区动力学在耐药性中的作用:C亚型的阐述
Viruses. 2025 Jul 26;17(8):1044. doi: 10.3390/v17081044.
2
HIV-1 protease inhibitors and mechanisms of HIV-1's resistance.HIV-1蛋白酶抑制剂与HIV-1耐药机制
Glob Health Med. 2024 Dec 31;6(6):357-362. doi: 10.35772/ghm.2024.01073.
3
Natural Polymorphisms D60E and I62V Stabilize a Closed Conformation in HIV-1 Protease in the Absence of an Inhibitor or Substrate.天然多态性 D60E 和 I62V 使 HIV-1 蛋白酶在没有抑制剂或底物的情况下稳定在封闭构象。
Viruses. 2024 Feb 2;16(2):236. doi: 10.3390/v16020236.
4
Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance.HIV-1 对第五代蛋白酶抑制剂耐药性的选择揭示了两种独立的高耐药水平的途径。
Elife. 2023 Mar 15;12:e80328. doi: 10.7554/eLife.80328.
5
HIV and Drug-Resistant Subtypes.人类免疫缺陷病毒与耐药亚型
Microorganisms. 2023 Jan 15;11(1):221. doi: 10.3390/microorganisms11010221.
6
Elasticity-Associated Functionality and Inhibition of the HIV Protease.弹性相关功能和 HIV 蛋白酶的抑制作用。
Adv Exp Med Biol. 2022;1371:79-108. doi: 10.1007/5584_2021_655.
7
Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning.通过分子动力学和机器学习来破译耐药性和效力丧失的复杂机制。
J Chem Theory Comput. 2021 Apr 13;17(4):2054-2064. doi: 10.1021/acs.jctc.0c01244. Epub 2021 Mar 30.
8
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.直接作用抗病毒药物及其他药物的耐药性规避药物设计策略。
Chem Rev. 2021 Mar 24;121(6):3238-3270. doi: 10.1021/acs.chemrev.0c00648. Epub 2021 Jan 7.
9
Darunavir-Resistant HIV-1 Protease Constructs Uphold a Conformational Selection Hypothesis for Drug Resistance.达芦那韦耐药 HIV-1 蛋白酶构建体支持耐药性的构象选择假说。
Viruses. 2020 Nov 8;12(11):1275. doi: 10.3390/v12111275.
10
Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.高度耐药的 HIV-1 蛋白酶由于突变簇导致亚单位间相互作用减弱。
FEBS J. 2020 Aug;287(15):3235-3254. doi: 10.1111/febs.15207. Epub 2020 Jan 23.

本文引用的文献

1
Closing of the flaps of HIV-1 protease induced by substrate binding: a model of a flap closing mechanism in retroviral aspartic proteases.底物结合诱导HIV-1蛋白酶的瓣片关闭:逆转录病毒天冬氨酸蛋白酶中瓣片关闭机制的模型
Biochemistry. 2006 May 30;45(21):6606-14. doi: 10.1021/bi060188k.
2
Restrained molecular dynamics simulations of HIV-1 protease: the first step in validating a new target for drug design.HIV-1蛋白酶的受限分子动力学模拟:药物设计新靶点验证的第一步。
Biopolymers. 2006 Jun 15;82(3):272-84. doi: 10.1002/bip.20497.
3
Drug resistance of HIV-1 protease against JE-2147: I47V mutation investigated by molecular dynamics simulation.
Chem Biol Drug Des. 2006 Feb;67(2):155-61. doi: 10.1111/j.1747-0285.2006.00348.x.
4
HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations.在分子动力学模拟中,HIV-1蛋白酶的侧翼会自发打开并重新闭合。
Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):915-20. doi: 10.1073/pnas.0508452103. Epub 2006 Jan 17.
5
Update of the drug resistance mutations in HIV-1: Fall 2005.2005年秋季HIV-1耐药性突变的更新情况。
Top HIV Med. 2005 Oct-Nov;13(4):125-31.
6
Flap opening mechanism of HIV-1 protease.HIV-1蛋白酶的瓣打开机制。
J Mol Graph Model. 2006 May;24(6):465-74. doi: 10.1016/j.jmgm.2005.08.008. Epub 2005 Sep 26.
7
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.HIV-1蛋白酶和逆转录酶突变:B亚型分离株中与抗逆转录病毒治疗的相关性及对耐药性监测的意义
J Infect Dis. 2005 Aug 1;192(3):456-65. doi: 10.1086/431601. Epub 2005 Jul 5.
8
Solvation influences flap collapse in HIV-1 protease.溶剂化作用影响HIV-1蛋白酶中的蛋白水解片段折叠。
Proteins. 2005 Jan 1;58(1):119-25. doi: 10.1002/prot.20274.
9
Update of the drug resistance mutations in HIV-1: 2004.2004年HIV-1耐药性突变的更新情况。
Top HIV Med. 2004 Oct-Nov;12(4):119-24.
10
HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.野生型和V82F/I84V突变体的HIV-1蛋白酶分子动力学:对耐药性的可能贡献及潜在的药物新靶点
Protein Sci. 2004 Apr;13(4):1108-23. doi: 10.1110/ps.03468904.